<?xml version='1.0' encoding='utf-8'?>
<document id="28940476"><sentence text="Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions." /><sentence text="We investigated whether CYP2D6 extensive metabolizers carrying a nonfunctional allele are at higher risk of phenoconversion to poor metabolizers in the presence of CYP2D6 inhibitors" /><sentence text=" Seventeen homozygous carriers of two fully-functional alleles and 17 heterozygous carriers of one fully-functional and one nonfunctional allele participated in this trial" /><sentence text=" Dextromethorphan 5 mg and tramadol 10 mg were given at each of the three study sessions"><entity charOffset="1-17" id="DDI-PubMed.28940476.s4.e0" text="Dextromethorphan" /><entity charOffset="27-35" id="DDI-PubMed.28940476.s4.e1" text="tramadol" /><pair ddi="false" e1="DDI-PubMed.28940476.s4.e0" e2="DDI-PubMed.28940476.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28940476.s4.e0" e2="DDI-PubMed.28940476.s4.e1" /></sentence><sentence text=" CYP2D6 was inhibited by duloxetine 60 mg (session 2) and paroxetine 20 mg (session 3)"><entity charOffset="25-35" id="DDI-PubMed.28940476.s5.e0" text="duloxetine" /><entity charOffset="58-68" id="DDI-PubMed.28940476.s5.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.28940476.s5.e0" e2="DDI-PubMed.28940476.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28940476.s5.e0" e2="DDI-PubMed.28940476.s5.e1" /></sentence><sentence text=" A higher rate of phenoconversion to intermediate metabolizers with duloxetine (71% vs"><entity charOffset="68-78" id="DDI-PubMed.28940476.s6.e0" text="duloxetine" /></sentence><sentence text=" 25%, P = 0" /><sentence text="009) and to poor metabolizers with paroxetine (94% vs"><entity charOffset="35-45" id="DDI-PubMed.28940476.s8.e0" text="paroxetine" /></sentence><sentence text=" 56%, P = 0" /><sentence text="011) was observed in heterozygous than homozygous extensive metabolizers" /><sentence text=" The magnitude of drug-drug interaction between dextromethorphan and paroxetine was higher in homozygous than in heterozygous subjects (14"><entity charOffset="48-64" id="DDI-PubMed.28940476.s11.e0" text="dextromethorphan" /><entity charOffset="69-79" id="DDI-PubMed.28940476.s11.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.28940476.s11.e0" e2="DDI-PubMed.28940476.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28940476.s11.e0" e2="DDI-PubMed.28940476.s11.e1" /></sentence><sentence text="6 vs" /><sentence text=" 8" /><sentence text="5, P &lt; 0" /><sentence text="028)" /><sentence text=" Our study suggests that genetic extensive metabolizers may not represent a homogenous population and that available genetic data should be considered when addressing drug-drug interactions in clinical practice" /><sentence text="" /></document>